Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S. Ueda T, et al. Among authors: nakatsura t. Cancer Sci. 2020 May;111(5):1478-1490. doi: 10.1111/cas.14374. Epub 2020 Mar 31. Cancer Sci. 2020. PMID: 32133731 Free PMC article.
Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H, Hirata S, Yoshitake Y, Motomura Y, Fukuma D, Kurisaki A, Nakatsura T, Nishimura Y, Senju S. Matsuyoshi H, et al. Among authors: nakatsura t. Cancer Sci. 2005 Dec;96(12):889-96. doi: 10.1111/j.1349-7006.2005.00123.x. Cancer Sci. 2005. PMID: 16367909 Free article.
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Shirakawa H, et al. Among authors: nakatsura t. Cancer Sci. 2009 Aug;100(8):1403-7. doi: 10.1111/j.1349-7006.2009.01206.x. Epub 2009 May 4. Cancer Sci. 2009. PMID: 19496787 Free article.
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T. Yoshikawa T, et al. Among authors: nakatsura t. Cancer Sci. 2011 May;102(5):918-25. doi: 10.1111/j.1349-7006.2011.01896.x. Epub 2011 Mar 4. Cancer Sci. 2011. PMID: 21281401 Free article. Clinical Trial.
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T, Komori H, Baba H, Fujiwara T, Nakatsura T. Nobuoka D, et al. Among authors: nakatsura t. Int J Oncol. 2012 Jan;40(1):63-70. doi: 10.3892/ijo.2011.1202. Epub 2011 Sep 15. Int J Oncol. 2012. PMID: 21922136 Clinical Trial.
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Sawada Y, et al. Among authors: nakatsura t. Clin Cancer Res. 2012 Jul 1;18(13):3686-96. doi: 10.1158/1078-0432.CCR-11-3044. Epub 2012 May 10. Clin Cancer Res. 2012. PMID: 22577059 Clinical Trial.
141 results